Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps

A Santaris official also confirmed that an option giving GlaxoSmithKline an option to license the drug has expired, and that deals with other companies are underway.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.